Nonetheless, IL-6 blockade remains an important option for patients who cannot tolerate other therapies or in whom IL-6–mediated symptoms (e.g., systemic inflammation, anemia) are prominent (65). This evidence concerns the gene IL6 and anemia (phenotype).